对抗剂配体与REV-ERBα结合的机制
Mohammad Homaidur Rahman1,2, Lamees Hegazy3,4
1Center for Clinical Pharmacology, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, MO, USA.
研究人员使用高斯加速分子动力学 (GaMD) 来绘制SR8278,REV-ERBα抗剂如何与受体结合. 这种方法有助于开发针对核激素受体的新药.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- REV-ERBα是一种核激素受体,调节昼夜节律,新陈代谢和炎症.
- 对于REV-ERBα抗剂,有限的化学探针和缺乏结构数据阻碍了治疗开发.
- SR8278是唯一已确定的REV-ERBα的合成抗剂.
研究的目的:
- 使用计算模拟研究REV-ERBα抗剂SR8278的结合途径.
- 评估高斯加速分子动力学 (GaMD) 对于研究核激素受体药理学的有用性.
- 为药物发现提供有关联体受体相互作用的见解.
主要方法:
- 使用了高斯加速分子动力学 (GaMD) 模拟.
- 模拟了SR8278与REV-ERBα的结合.
- 为了进行比较,还模拟了STL1267的联体结合,具有可用的X射线结构.
主要成果:
- GaMD成功捕获了SR8278和STL1267的结合到REV-ERBα的正位.
- 模拟预测了连接体结合途径和参与SR8278结合的关键氨基酸残留物.
- 这项研究验证了GaMD在建模蛋白 - 配体相互作用中的有效性.
结论:
- GaMD是一种有效的计算工具,用于研究蛋白质-连接体相互作用,特别是核激素受体.
- 这种方法可以指导开发针对REV-ERBα的新疗法.
- 了解连接体结合途径对于合理的药物设计至关重要.
更多相关视频
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
09:07Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
相关概念视频
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Ligand-Gated Ion Channel Receptor: Gating Mechanism
